AKT通过限制FOXO活性维持多发性骨髓瘤细胞的代谢适应性
本研究探讨AKT通过负调控FOXO转录因子维持多发性骨髓瘤(MM)细胞代谢适应性的机制。结果显示FOXO转录因子抑制糖酵解、三羧酸循环和氧化磷酸化相关关键代谢基因的表达,而AKT对FOXO的抑制是维持MM细胞糖酵解和三羧酸循环活性所必需,且FOXO依赖的糖酵解和三羧酸循环相关基因抑制与患者良好预后相关。
要点
- AKT负调控FOXO转录因子可防止MM细胞代谢关闭,维持其代谢适应性。
- FOXO转录因子抑制糖酵解、三羧酸循环和氧化磷酸化相关关键代谢基因表达。
- FOXO依赖的糖酵解和三羧酸循环相关基因抑制与MM患者良好预后相关。
核心结论
- AKT对FOXO的抑制对于维持MM细胞糖酵解和三羧酸循环活性至关重要,并预测患者生存。
研究设计与样本
- 本研究为实验室研究,探讨AKT通过负调控FOXO转录因子调控MM细胞代谢的机制,并在大样本MM患者队列中分析FOXO依赖的基因抑制与预后的相关性。
主要发现
- AKT对FOXO转录因子的负调控是防止MM细胞代谢关闭的关键,有助于其代谢适应性。
- FOXO转录因子抑制糖酵解、三羧酸循环和氧化磷酸化相关关键代谢基因的表达。
- FOXO依赖的糖酵解和三羧酸循环相关基因抑制与大样本MM患者队列的良好预后相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolic alterations are important cancer-associated features that allow cancer cell transformation and survival under stress conditions. Multiple myeloma (MM) plasma cells show increased glycolysis and oxidative phosphorylation (OXPHOS), which are characteristics associated with recurrent genetic aberrations that drive the proliferation and survival of MM cells. The protein kinase B/AKT acts as a central node in cellular metabolism and is constitutively active in MM cells. Despite the known role of AKT in modulating cellular metabolism, little is known about the downstream factors of AKT that control the metabolic adaptability of MM cells. Here, we demonstrate that negative regulation of the forkhead box O (FOXO) transcription factors (TFs) by AKT is crucial to prevent the metabolic shutdown in MM cells, thus contributing to their metabolic adaptability. Our results demonstrate that the expression of several key metabolic genes involved in glycolysis, the tricarboxylic acid (TCA) cycle, and OXPHOS are repressed by FOXO TFs. Moreover, the FOXO-dependent repression of glycolysis- and TCA-associated genes correlates with a favorable prognosis in a large cohort of patients with MM. Our data suggest that repression of FOXO by AKT is essential to sustain glycolysis and the TCA cycle activity in MM cells and, as such, predicts patient survival.
引用
- Bloedjes TA, de Wilde G, Khan GH, et al. AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activity. Blood Adv. 2023. PMID: 36322819. doi:10.1182/bloodadvances.2022007383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。